MetaCap

Tango Therapeutics Inc. (TNGX)

NASDAQ: TNGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

21.73-0.98 (-4.32%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TNGX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.38
52-week range
8.30 – 34.39
Day range
21.63 – 23.05
Volume / Avg
1.74M / 3.41M
Beta
—

52-week range

$8.30$34.39

TNGX stock today

Tango Therapeutics (TNGX) closed at $21.73 on Nov 20, down 4.32% (-$0.98), versus the S&P 500's 3.70% decline. Shares are 36.8% below their 52-week high of $34.39, set on Jun 17, 2026 and 161.8% above the 52-week low of $8.30, in the middle of the past year's range. TNGX is up 145.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 116.7%.

Tango Therapeutics has posted a net loss over the last twelve months (EPS of -$1.38), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Tango Therapeutics

Company profile

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Malte Peters M.D.
Headquarters
Boston, MA
Employees
137
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Tango Therapeutics generated $62.4 million in revenue, up 48.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Tango Therapeutics reported a net loss of $101.6 million, compared with a loss of $130.3 million a year earlier. Operating margin was -178.4%.

Tango Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$62.38M$42.07M$36.53M$24.86M$37.04M
Growth+48.29%+15.17%+46.93%-32.89%+383.83%
Net income$-101.59M$-130.30M$-101.74M$-108.18M$-58.23M
EPS (diluted)$-0.87$-1.19$-1.08$-1.23$-0.94

Analyst forecast

Forecast

Consensus (13 analysts)

strong_buy

Avg. price target

$47.00+116.29%

  • Strong buy 1
  • Buy 11
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $24.00High $68.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.39 vs $-0.34
Surprise
-14.71%

TNGX news

All TNGX news

Tango Therapeutics peers

Health Care sector
TNGX peer companies
CompanyPrice% ChgMarket capCompare
OGNOrganon & Co.13.89-0.14%$3.65Bvs TNGX
XENEXenon Pharmaceuticals Inc.37.04-1.38%$3.64Bvs TNGX
PBLSParabilis Medicines Inc.27.44-0.67%$3.44Bvs TNGX
ELVNEnliven Therapeutics Inc.46.53+0.26%$3.42Bvs TNGX
IRONDisc Medicine Inc.75.14-1.27%$3.42Bvs TNGX
VRDNViridian Therapeutics Inc.29.96-4.71%$3.40Bvs TNGX
AMLXAmylyx Pharmaceuticals Inc.26.02-0.69%$3.35Bvs TNGX
ARQTArcutis Biotherapeutics Inc.26.36-2.98%$3.33Bvs TNGX

Indexes, lists and sector

Tango Therapeutics stock FAQ

What is Tango Therapeutics's stock price today?

TNGX last traded at $21.73 as of Nov 20, 4:00 PM EST, down 4.32% on the day. Prices are delayed at least 15 minutes.

Who is Tango Therapeutics's CEO?

Dr. Malte Peters M.D. is the chief executive officer of Tango Therapeutics Inc., which has about 137 employees.

What is the TNGX 52-week high?

The 52-week high for TNGX is $34.39 and the 52-week low is $8.30. The stock is currently 36.8% below its high.

Compare TNGX